Cessatech Beheer

Beheer criteriumcontroles 1/4

De CEO Cessatech is Jes Trygved, benoemd in Jan2020, heeft een ambtstermijn van 4.83 jaar. bezit rechtstreeks 5.32% van de aandelen van het bedrijf, ter waarde DKK 12.61M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.9 jaar en 4.3 jaar.

Belangrijke informatie

Jes Trygved

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.8yrs
Eigendom CEO	5.3%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Is Cessatech (NGM:CESSA) In A Good Position To Invest In Growth?

Aug 03

CEO

Jes Trygved (51 yo)

4.8yrs

Tenure

Mr. Jes Trygved serves as Chief Executive Officer at Cessatech A/S (formerly known as Cessatech ApS) since 2020. Mr. Trygved has experience within the biotech and pharmaceutical industry including time spe...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jes Trygved	Chief Executive Officer	4.8yrs	geen gegevens	5.32% DKK 12.6m
Martin Juhl	Chief Scientific Officer and Head of CMC	less than a year	geen gegevens	geen gegevens
Louise Bak	Head of Regulatory Affairs	2.7yrs	geen gegevens	geen gegevens
Malene Cording	Head of Clinical Development & Operations	less than a year	geen gegevens	geen gegevens
Mai Gregersen	Head of Quality Assurance	less than a year	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

Ervaren management: Het managementteam van CESSA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Flemming Jensen	Independent Director	4.3yrs	geen gegevens	geen gegevens
Martin Olin	Independent Chairman of the Board	4.3yrs	geen gegevens	2.05% DKK 4.9m
Charlotte Videbaek	Independent Director	4.3yrs	geen gegevens	1% DKK 2.4m
Rachel Gravesen	Director	2.8yrs	geen gegevens	1.17% DKK 2.8m
Anders Dombernowsky-Toft	Director	less than a year	geen gegevens	0.29% DKK 691.7k

4.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CESSA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Cessatech Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Cessatech A/S Announces Board Changes

Cessatech A/S, Annual General Meeting, Mar 27, 2024

Cessatech A/S, Annual General Meeting, Mar 17, 2023

High number of new and inexperienced directors

Cessatech A/S, Annual General Meeting, Mar 26, 2021

Recent updates

Cessatech A/S to Report Q3, 2024 Results on Nov 13, 2024

Is Cessatech (NGM:CESSA) In A Good Position To Invest In Growth?

Cessatech A/S to Report Q2, 2024 Results on Aug 21, 2024

Cessatech A/S Announces Board Changes

Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001

Cessatech A/S to Report Q1, 2024 Results on May 15, 2024

New major risk - Negative shareholders equity

Cessatech A/S, Annual General Meeting, Mar 27, 2024

New minor risk - Shareholder dilution

Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children

Cessatech A/S to Report Q3, 2023 Results on Nov 16, 2023

Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001

Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation

Cessatech A/S to Report Q2, 2023 Results on Aug 24, 2023

Cessatech A/S, Annual General Meeting, Mar 17, 2023

Cessatech A/S to Report Fiscal Year 2022 Results on Mar 03, 2023

High number of new and inexperienced directors

Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate

Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate

Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate

Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval

Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate

Cessatech Reports Successful Outcome of Bioavailability Trial 0204 with CT001

Cessatech A/S Expects to Report on its Bioavailability Trial 0204 Within Few Weeks

Cessatech Reports First Patient Dosed in Pharmacokinetic Trial in Children of Lead Product Candidate

Cessatech Reports Last Subject Dosed in Bioavailability Trial of Lead Product Candidate

Cessatech A/S, Annual General Meeting, Mar 26, 2021

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd